Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1992 Jun;55(6):450–453. doi: 10.1136/jnnp.55.6.450

High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect.

D H Miller 1, A J Thompson 1, S P Morrissey 1, D G MacManus 1, S G Moore 1, B E Kendall 1, I F Moseley 1, W I McDonald 1
PMCID: PMC1014899  PMID: 1619410

Abstract

The integrity of the blood-brain barrier (BBB) in multiple sclerosis (MS) was monitored by serial gadolinium-(Gd)-DTPA enhanced MRI during and after the treatment of acute relapses with a three day course of high dose intravenous methylprednisolone (IVMP). During treatment there was a rapid reduction of BBB abnormalities in 96% of enhancing lesions. In spite of sustained clinical improvement, many lesions re-enhanced within a few days of stopping IVMP, and new lesions frequently appeared within one month. It is possible that the rapid, albeit transient, reversal of BBB abnormalities contributes to the accelerated recovery from relapses associated with IVMP treatment.

Full text

PDF
450

Images in this article

451Image
on p.451

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barkhof F., Hommes O. R., Scheltens P., Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology. 1991 Aug;41(8):1219–1222. doi: 10.1212/wnl.41.8.1219. [DOI] [PubMed] [Google Scholar]
  2. Barnes M. P., Bateman D. E., Cleland P. G., Dick D. J., Walls T. J., Newman P. K., Saunders M., Tilley P. J. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry. 1985 Feb;48(2):157–159. doi: 10.1136/jnnp.48.2.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bastianello S., Pozzilli C., Bernardi S., Bozzao L., Fantozzi L. M., Buttinelli C., Fieschi C. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology. 1990 Apr;40(4):591–595. doi: 10.1212/wnl.40.4.591. [DOI] [PubMed] [Google Scholar]
  4. Compston D. A., Milligan N. M., Hughes P. J., Gibbs J., McBroom V., Morgan B. P., Campbell A. K. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results. J Neurol Neurosurg Psychiatry. 1987 May;50(5):517–522. doi: 10.1136/jnnp.50.5.517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Durelli L., Cocito D., Riccio A., Barile C., Bergamasco B., Baggio G. F., Perla F., Delsedime M., Gusmaroli G., Bergamini L. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology. 1986 Feb;36(2):238–243. doi: 10.1212/wnl.36.2.238. [DOI] [PubMed] [Google Scholar]
  6. Felson D. T., Anderson J. J. Across-study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet. 1987 Apr 18;1(8538):902–906. doi: 10.1016/s0140-6736(87)92870-4. [DOI] [PubMed] [Google Scholar]
  7. Hafler D. A., Weiner H. L. In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis. Ann Neurol. 1987 Jul;22(1):89–93. doi: 10.1002/ana.410220121. [DOI] [PubMed] [Google Scholar]
  8. Harris J. O., Frank J. A., Patronas N., McFarlin D. E., McFarland H. F. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol. 1991 May;29(5):548–555. doi: 10.1002/ana.410290515. [DOI] [PubMed] [Google Scholar]
  9. Kermode A. G., Thompson A. J., Tofts P., MacManus D. G., Kendall B. E., Kingsley D. P., Moseley I. F., Rudge P., McDonald W. I. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain. 1990 Oct;113(Pt 5):1477–1489. doi: 10.1093/brain/113.5.1477. [DOI] [PubMed] [Google Scholar]
  10. Kermode A. G., Tofts P. S., Thompson A. J., MacManus D. G., Rudge P., Kendall B. E., Kingsley D. P., Moseley I. F., du Boulay E. P., McDonald W. I. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology. 1990 Feb;40(2):229–235. doi: 10.1212/wnl.40.2.229. [DOI] [PubMed] [Google Scholar]
  11. Kesselring J., Miller D. H., MacManus D. G., Johnson G., Milligan N. M., Scolding N., Compston D. A., McDonald W. I. Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. J Neurol Neurosurg Psychiatry. 1989 Jan;52(1):14–17. doi: 10.1136/jnnp.52.1.14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. MILLER H., NEWELL D. J., RIDLEY A. Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (A.C.T.H.). Lancet. 1961 Nov 18;2(7212):1120–1122. doi: 10.1016/s0140-6736(61)91030-3. [DOI] [PubMed] [Google Scholar]
  13. Miller D. H., Rudge P., Johnson G., Kendall B. E., Macmanus D. G., Moseley I. F., Barnes D., McDonald W. I. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 1988 Aug;111(Pt 4):927–939. doi: 10.1093/brain/111.4.927. [DOI] [PubMed] [Google Scholar]
  14. Milligan N. M., Newcombe R., Compston D. A. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry. 1987 May;50(5):511–516. doi: 10.1136/jnnp.50.5.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  16. Rose A. S., Kuzma J. W., Kurtzke J. F., Namerow N. S., Sibley W. A., Tourtellotte W. W. Cooperative study in the evaluation of therapy in multiple sclerosis. ACTH vs. placebo--final report. Neurology. 1970 May;20(5):1–59. doi: 10.1212/wnl.20.5_part_2.1. [DOI] [PubMed] [Google Scholar]
  17. Thompson A. J., Kennard C., Swash M., Summers B., Yuill G. M., Shepherd D. I., Roche S., Perkin G. D., Loizou L. A., Ferner R. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology. 1989 Jul;39(7):969–971. doi: 10.1212/wnl.39.7.969. [DOI] [PubMed] [Google Scholar]
  18. Thompson A. J., Kermode A. G., Wicks D., MacManus D. G., Kendall B. E., Kingsley D. P., McDonald W. I. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol. 1991 Jan;29(1):53–62. doi: 10.1002/ana.410290111. [DOI] [PubMed] [Google Scholar]
  19. Tofts P. S., Kermode A. G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med. 1991 Feb;17(2):357–367. doi: 10.1002/mrm.1910170208. [DOI] [PubMed] [Google Scholar]
  20. Tracey K. J., Lowry S. F., Beutler B., Cerami A., Albert J. D., Shires G. T. Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential. J Exp Med. 1986 Oct 1;164(4):1368–1373. doi: 10.1084/jem.164.4.1368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Triarhou L. C., Herndon R. M. The effect of dexamethasone on L-alpha-lysophosphatidyl choline (lysolecithin)-induced demyelination of the rat spinal cord. Arch Neurol. 1986 Feb;43(2):121–125. doi: 10.1001/archneur.1986.00520020015008. [DOI] [PubMed] [Google Scholar]
  22. Troiano R., Hafstein M., Ruderman M., Dowling P., Cook S. Effect of high-dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis. Ann Neurol. 1984 Mar;15(3):257–263. doi: 10.1002/ana.410150309. [DOI] [PubMed] [Google Scholar]
  23. Warren K. G., Catz I., Jeffrey V. M., Carroll D. J. Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations. Can J Neurol Sci. 1986 Feb;13(1):25–30. doi: 10.1017/s0317167100035757. [DOI] [PubMed] [Google Scholar]
  24. Youl B. D., Turano G., Miller D. H., Towell A. D., MacManus D. G., Moore S. G., Jones S. J., Barrett G., Kendall B. E., Moseley I. F. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain. 1991 Dec;114(Pt 6):2437–2450. doi: 10.1093/brain/114.6.2437. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES